McGuire Investment Group LLC Purchases 29 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)


Share on StockTwits

McGuire Investment Group LLC increased its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.1% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 30,083 shares of the medical research company’s stock after purchasing an additional 29 shares during the period. Thermo Fisher Scientific comprises about 3.5% of McGuire Investment Group LLC’s investment portfolio, making the stock its 7th biggest holding. McGuire Investment Group LLC’s holdings in Thermo Fisher Scientific were worth $14,012,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Dimension Capital Management LLC acquired a new stake in Thermo Fisher Scientific during the 3rd quarter worth about $31,000. Kessler Investment Group LLC purchased a new position in Thermo Fisher Scientific during the third quarter valued at approximately $33,000. Column Capital Advisors LLC lifted its position in Thermo Fisher Scientific by 108.3% in the 3rd quarter. Column Capital Advisors LLC now owns 75 shares of the medical research company’s stock worth $33,000 after buying an additional 39 shares in the last quarter. Anderson Fisher LLC purchased a new stake in Thermo Fisher Scientific in the 3rd quarter worth approximately $34,000. Finally, ARK Investment Management LLC acquired a new stake in shares of Thermo Fisher Scientific during the 3rd quarter valued at $34,000. Hedge funds and other institutional investors own 88.12% of the company’s stock.

In related news, COO Mark Stevenson sold 14,113 shares of the business’s stock in a transaction on Friday, December 4th. The stock was sold at an average price of $476.46, for a total value of $6,724,279.98. Following the completion of the sale, the chief operating officer now directly owns 58,005 shares in the company, valued at approximately $27,637,062.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction on Monday, October 26th. The shares were sold at an average price of $479.94, for a total value of $4,799,400.00. Following the completion of the transaction, the chief executive officer now directly owns 228,694 shares in the company, valued at $109,759,398.36. The disclosure for this sale can be found here. Insiders have sold a total of 38,246 shares of company stock valued at $18,220,461 in the last ninety days. Insiders own 0.44% of the company’s stock.

Shares of NYSE TMO traded up $2.94 during trading hours on Wednesday, hitting $501.71. The company had a trading volume of 1,388,587 shares, compared to its average volume of 1,980,348. Thermo Fisher Scientific Inc. has a 1-year low of $250.21 and a 1-year high of $532.57. The company has a quick ratio of 2.02, a current ratio of 2.62 and a debt-to-equity ratio of 0.69. The firm’s 50 day moving average is $470.61 and its 200-day moving average is $441.63. The stock has a market capitalization of $198.85 billion, a P/E ratio of 53.98, a price-to-earnings-growth ratio of 1.86 and a beta of 0.98.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, October 21st. The medical research company reported $5.63 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $4.37 by $1.26. Thermo Fisher Scientific had a net margin of 14.12% and a return on equity of 18.18%. The company had revenue of $8.25 billion for the quarter, compared to analysts’ expectations of $7.68 billion. During the same period in the prior year, the firm earned $2.94 EPS. Thermo Fisher Scientific’s quarterly revenue was up 31.6% compared to the same quarter last year. On average, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 15.99 earnings per share for the current year.

Thermo Fisher Scientific declared that its board has approved a share buyback plan on Thursday, November 5th that authorizes the company to repurchase $2.50 billion in shares. This repurchase authorization authorizes the medical research company to buy up to 1.2% of its shares through open market purchases. Shares repurchase plans are typically an indication that the company’s leadership believes its shares are undervalued.

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 15th. Shareholders of record on Tuesday, December 15th will be issued a dividend of $0.22 per share. This represents a $0.88 annualized dividend and a yield of 0.18%. The ex-dividend date is Monday, December 14th. Thermo Fisher Scientific’s dividend payout ratio is 7.13%.

Several brokerages recently weighed in on TMO. KeyCorp started coverage on shares of Thermo Fisher Scientific in a research report on Monday, November 9th. They set a “sector weight” rating and a $550.00 price objective on the stock. Credit Suisse Group increased their price target on shares of Thermo Fisher Scientific from $556.00 to $580.00 in a report on Tuesday. Robert W. Baird boosted their price objective on shares of Thermo Fisher Scientific from $512.00 to $523.00 and gave the stock an “outperform” rating in a report on Wednesday, December 2nd. Smith Barney Citigroup lowered Thermo Fisher Scientific from a “buy” rating to a “neutral” rating in a report on Wednesday, December 16th. Finally, The Goldman Sachs Group began coverage on shares of Thermo Fisher Scientific in a report on Wednesday, December 2nd. They issued a “buy” rating and a $570.00 price target on the stock. Six analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $492.58.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery and production of drugs and vaccines, and diagnosis of diseases to pharmaceutical, biotechnology, agricultural, clinical, academic, and government markets.

Read More: Cost of Equity For A Business, Investors

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.